進行性非小細胞肺がん (NSCLC) の経済的負担:体系的な文献レビュー
Nick Jovanoski1, Gavneet Kaur2, Hemlata Shukla2
1F. Hoffmann-La Roche, Basel, Switzerland.
Journal of medical economics
|February 22, 2026
まとめ
先進性非小細胞肺癌 (NSCLC) の患者は,医療資源の利用が高く,費用が大きくなります. 脳転移はこれらの負担を大幅に増加させ,免疫療法は化学療法よりもコストが低いことを示しています.
科学分野:
- 腫瘍学 腫瘍学
- 健康経済学 医療経済学
- 公衆衛生は公衆衛生である.
背景:
- 先進性非小細胞肺癌 (NSCLC) は,経済的に大きな課題となっています.
- 経済的な負担を理解することは,リソースの配分と患者ケア戦略において極めて重要です.
研究 の 目的:
- 先進 (ステージIIIB/C/IV) のNSCLCの経済的負担を体系的に検討する.
- 医療資源利用 (HCRU) と医療費に影響を与える要因を特定する.
主な方法:
- 2011年以降の出版物の体系的なレビュー.
- 検索により,HCRU (入院,診察,検査) と直接/間接コストを報告する研究が特定されました.
- データ抽出は,経済結果と影響要因に焦点を当てました.
主要な成果:
- 先進的なNSCLCの患者は,頻繁な入院や診察を含む高いHCRUを示します.
- 直接コストは国によって大きく異なっており,米国,韓国,ドイツ,英国が最も高い.
- 薬費,門診費,入院費は主要なコストドライバーであり,免疫療法は化学療法よりも低いHCRUとコストに関連していました.
結論:
- 先進的なNSCLCの患者は,脳転移や治療の種類などの要因の影響を受け,重要なHCRUと経済的コストに直面します.
- 費用とHCRUは,脳/中枢神経系転移の患者では著しく高かった.
- 比較性は通貨の違いと研究の異質性によって制限され,さらなる定量合成が必要である.
関連する概念動画
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
02:49Cancer Therapies
10.3K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.3K
01:21Cancer Survival Analysis
793
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
793